Evidence supporting the use of: Cannabigerol
For the health condition: Crohn's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabigerol (CBG) is a non-psychoactive cannabinoid found in cannabis plants. Its use to support or treat Crohn's Disease is primarily justified by early-stage scientific exploration, rather than long-standing tradition or robust clinical evidence. Preclinical studies, mostly in animal models, suggest that CBG possesses anti-inflammatory properties that could be beneficial in inflammatory bowel diseases (IBD) like Crohn's Disease. For instance, a notable 2013 study in mice with induced colitis found that CBG reduced inflammation and oxidative stress in the colon (Borrelli et al., 2013). CBG appears to modulate the endocannabinoid system, which plays a role in gut homeostasis and immune response.

However, there are currently no published clinical trials investigating CBG specifically in people with Crohn's Disease. Most available evidence is limited to animal studies and in vitro data. While some Crohn's patients may use cannabinoid products (including CBG) as complementary therapies, this is based on anecdotal reports and extrapolation from other cannabinoids like CBD or THC, which have more clinical research related to IBD. In summary, CBG’s use for Crohn’s Disease is supported by preliminary scientific research, but the evidence is weak, and well-designed human trials are lacking. Patients should consult healthcare professionals before considering CBG for Crohn’s Disease management.

More about Cannabigerol
More about Crohn's Disease

Products containing Cannabigerol

We currently have no products on Vitabase that contain this ingredient.